We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Neurology

Journal Scan / Research · March 30, 2021

Second Intravenous Immunoglobulin Dose in Patients With Guillain-Barré Syndrome With Poor Prognosis

The Lancet Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Neurology
Second Intravenous Immunoglobulin Dose in Patients With Guillain-Barré Syndrome With Poor Prognosis (SID-GBS): A Double-Blind, Randomised, Placebo-Controlled Trial
Lancet Neurol 2021 Apr 01;20(4)275-283, C Walgaard, BC Jacobs, HF Lingsma, EW Steyerberg, B van den Berg, AY Doets, SE Leonhard, C Verboon, R Huizinga, J Drenthen, S Arends, IK Budde, RP Kleyweg, K Kuitwaard, MFG van der Meulen, JPA Samijn, FH Vermeij, JBM Kuks, GW van Dijk, PW Wirtz, F Eftimov, AJ van der Kooi, MPJ Garssen, CJ Gijsbers, MC de Rijk, LH Visser, RJ Blom, WHJP Linssen, EL van der Kooi, JJGM Verschuuren, R van Koningsveld, RJG Dieks, HJ Gilhuis, K Jellema, TC van der Ree, HME Bienfait, CG Faber, H Lovenich, BGM van Engelen, RJ Groen, ISJ Merkies, BW van Oosten, WL van der Pol, WDM van der Meulen, UA Badrising, M Stevens, AJ Breukelman, CP Zwetsloot, MM van der Graaff, M Wohlgemuth, RAC Hughes, DR Cornblath, PA van Doorn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading